Skip to main content

Market Overview

Amicus Therapeutics Concludes Pre-BLA Meeting With FDA For AT-GAA In Pompe Disease

Share:
Amicus Therapeutics Concludes Pre-BLA Meeting With FDA For AT-GAA In Pompe Disease
  • Amicus Therapeutics Inc (NASDAQ: FOLD) has completed a Type B Pre-Biologics License Application (BLA) meeting with the FDA for AT-GAA (cipaglucosidase alfa co-administered with miglustat) for Pompe disease.
  • Based on this formal pre-BLA meeting and the final written communication received from the FDA, Amicus intends to complete the rolling submission for cipaglucosidase alfa and submit a marketing application for miglustat.
  • Amicus intends to base its filings on evaluating the effects of AT-GAA in late-onset Pompe patients and its safety profile, which will include data from both the Phase 1/2 and Phase 3 PROPEL studies as well as data from the open-label extension study.
  • As part of the rolling BLA, Amicus previously submitted the non-clinical component of the cipaglucosidase alfa application and is on track to submit all of the remaining modules of the application by the end of the second quarter.
  • AT-GAA is an investigational two-component therapy that consists of cipaglucosidase alfa (ATB200), an enzyme replacement therapy administered in conjunction with miglustat (AT2221), an orally administered stabilizer of cipaglucosidase alfa.
  • Marketing applications for AT-GAA are expected to be submitted with the European Medicines Agency (EMA) in the second half of 2021.
  • Price Action: FOLD shares are up 4.4% at $10.27 in the premarket session on the last check Monday.
 

Related Articles (FOLD)

View Comments and Join the Discussion!

Posted-In: Briefs Pompe DiseaseBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com